Q2 2024 |
6 |
$843M |
$0 |
-$626M |
-$626M |
MRNA, SANA, FHTX, OMGA, MCRB
|
13F-HR |
8/14/2024, 04:00 PM |
Q1 2024 |
7 |
$1.52B |
+$5.00 |
-$19.6M |
-$19.6M |
MRNA, SANA, OMGA, FHTX, DNLI
|
13F-HR |
5/15/2024, 04:00 PM |
Q4 2023 |
7 |
$1.33B |
+$2.34M |
-$49.7M |
-$47.4M |
MRNA, SANA, OMGA, FHTX, DNLI
|
13F-HR |
2/14/2024, 04:00 PM |
Q3 2023 |
9 |
$1.38B |
+$33.4M |
-$389M |
-$356M |
MRNA, SANA, FHTX, OMGA, MCRB
|
13F-HR |
11/14/2023, 04:00 PM |
Q2 2023 |
10 |
$2.24B |
+$26.2M |
-$25M |
+$1.12M |
MRNA, SANA, OMGA, MCRB, FHTX
|
13F-HR |
8/14/2023, 04:00 PM |
Q1 2023 |
11 |
$2.57B |
$0 |
-$6.55M |
-$6.55M |
MRNA, OMGA, MCRB, SANA, FHTX
|
13F-HR |
5/15/2023, 04:00 PM |
Q4 2022 |
12 |
$2.84B |
+$3.32M |
$0 |
+$3.32M |
MRNA, SANA, MCRB, EVLO, FHTX
|
13F-HR |
2/14/2023, 01:00 PM |
Q3 2022 |
12 |
$2.38B |
+$63.2M |
-$2.82M |
+$60.4M |
MRNA, SANA, MCRB, OMGA, FHTX
|
13F-HR |
11/14/2022, 04:00 PM |
Q2 2022 |
12 |
$2.65B |
+$57.8M |
-$703M |
-$645M |
MRNA, SANA, FHTX, EVLO, OMGA
|
13F-HR |
8/15/2022, 04:02 PM |
Q1 2022 |
13 |
$4.26B |
+$16.2M |
$0 |
+$16.2M |
MRNA, SANA, RUBY, FHTX, OMGA
|
13F-HR |
5/16/2022, 03:01 PM |
Q4 2021 |
13 |
$6.47B |
$0 |
-$4.92M |
-$4.92M |
MRNA, SANA, RUBY, OMGA, FHTX
|
13F-HR |
2/14/2022, 03:01 PM |
Q3 2021 |
13 |
$9.55B |
+$488M |
$0 |
+$488M |
MRNA, SANA, RUBY, OMGA, FHTX
|
13F-HR |
11/15/2021, 04:01 PM |
Q2 2021 |
0 |
$0 |
$0 |
$0 |
|
|
13F-HR |
8/16/2021, 08:59 AM |
Q1 2021 |
0 |
$0 |
$0 |
$0 |
|
|
13F-HR |
5/17/2021, 04:30 PM |
Q4 2020 |
0 |
$0 |
$0 |
$0 |
|
|
13F-HR |
2/16/2021, 05:10 PM |
Q3 2020 |
8 |
$3.62B |
$0 |
-$708M |
-$708M |
MRNA, MCRB, KLDO, DNLI, RUBY
|
13F-HR |
11/16/2020, 04:00 PM |
Q2 2020 |
8 |
$3.44B |
+$58.7M |
-$706M |
-$648M |
MRNA, RUBY, DNLI, KLDO, EVLO
|
13F-HR |
8/13/2020, 04:01 PM |
Q1 2020 |
8 |
$2.13B |
$0 |
$0 |
|
MRNA, RUBY, DNLI, KLDO, MCRB
|
13F-HR |
5/14/2020, 04:16 PM |
Q4 2019 |
8 |
$1.79B |
$0 |
-$60.5M |
-$60.5M |
MRNA, RUBY, DNLI, KLDO, MCRB
|
13F-HR |
2/13/2020, 04:17 PM |
Q3 2019 |
7 |
$591M |
$0 |
$0 |
|
KLDO, DNLI, EVLO, MCRB, TMDX
|
13F-HR |
11/14/2019, 04:15 PM |
Q2 2019 |
10 |
$2.31B |
+$155M |
$0 |
+$155M |
MRNA, RUBY, KLDO, DNLI, EVLO
|
13F-HR |
8/13/2019, 04:15 PM |
Q1 2019 |
0 |
$0 |
$0 |
$0 |
|
|
13F-HR |
5/14/2019, 04:10 PM |
Q4 2018 |
7 |
$2.05B |
+$898M |
$0 |
+$898M |
MRNA, RUBY, EVLO, DNLI, MCRB
|
13F-HR |
2/12/2019, 06:44 PM |
Q3 2018 |
0 |
$0 |
$0 |
$0 |
|
|
13F-HR |
11/13/2018, 10:14 AM |
Q2 2018 |
0 |
$0 |
$0 |
$0 |
|
|
13F-HR |
8/7/2018, 04:26 PM |
Q1 2018 |
4 |
$345M |
$0 |
-$51.5M |
-$51.5M |
DNLI, MCRB, SYRS, QTRX
|
13F-HR |
5/15/2018, 04:05 PM |
Q4 2017 |
5 |
$394M |
+$183M |
$0 |
+$183M |
DNLI, MCRB, EDIT, QTRX, SYRS
|
13F-HR |
2/13/2018, 06:34 PM |
Q3 2017 |
0 |
$0 |
$0 |
$0 |
|
|
13F-HR |
11/3/2017, 10:23 AM |
Q2 2017 |
0 |
$0 |
$0 |
$0 |
|
|
13F-HR |
8/2/2017, 03:46 PM |
Q1 2017 |
7 |
$376M |
$0 |
-$1.77M |
-$1.77M |
MCRB, SYRS, EDIT, AGIO, RNAC
|
13F-HR |
5/10/2017, 04:28 PM |
Q4 2016 |
7 |
$307M |
$0 |
-$17.3M |
-$17.3M |
MCRB, SYRS, EDIT, AGIO, RNAC
|
13F-HR |
2/13/2017, 02:28 PM |
Q3 2016 |
7 |
$366M |
$0 |
$0 |
|
MCRB, SYRS, AGIO, EDIT, RNAC
|
13F-HR |
11/14/2016, 09:53 AM |